vs
艾伯维（ABBV）与STAAR SURGICAL CO（STAA）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是STAAR SURGICAL CO的339.5倍（$16.6B vs $49.0M）。艾伯维净利率更高（10.9% vs -69.9%，领先80.9%）。艾伯维同比增速更快（10.0% vs -35.8%）。艾伯维自由现金流更多（$4.9B vs $-5.1M）。过去两年艾伯维的营收复合增速更高（16.2% vs -18.4%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
STAAR Surgical是一家专注于眼科领域的全球医疗设备企业，主营可植入式隐形眼镜（ICL）及配套眼科手术耗材，为眼科医师提供微创视力矫正解决方案，产品覆盖北美、欧洲、亚太等全球主要市场。
ABBV vs STAA — 直观对比
营收规模更大
ABBV
是对方的339.5倍
$49.0M
营收增速更快
ABBV
高出45.9%
-35.8%
净利率更高
ABBV
高出80.9%
-69.9%
自由现金流更多
ABBV
多$4.9B
$-5.1M
两年增速更快
ABBV
近两年复合增速
-18.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $49.0M |
| 净利润 | $1.8B | $-34.2M |
| 毛利率 | 72.6% | 64.7% |
| 营业利润率 | 27.3% | -57.0% |
| 净利率 | 10.9% | -69.9% |
| 营收同比 | 10.0% | -35.8% |
| 净利润同比 | 8354.5% | -541.3% |
| 每股收益（稀释后） | $1.02 | $-0.69 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVSTAA
| Q4 25 | $16.6B | — | ||
| Q3 25 | $15.8B | — | ||
| Q2 25 | $15.4B | — | ||
| Q1 25 | $13.3B | — | ||
| Q4 24 | $15.1B | $49.0M | ||
| Q3 24 | $14.5B | $88.6M | ||
| Q2 24 | $14.5B | $99.0M | ||
| Q1 24 | $12.3B | $77.4M |
净利润ABBVSTAA
| Q4 25 | $1.8B | — | ||
| Q3 25 | $186.0M | — | ||
| Q2 25 | $938.0M | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $-22.0M | $-34.2M | ||
| Q3 24 | $1.6B | $10.0M | ||
| Q2 24 | $1.4B | $7.4M | ||
| Q1 24 | $1.4B | $-3.3M |
毛利率ABBVSTAA
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | 64.7% | ||
| Q3 24 | 70.9% | 77.3% | ||
| Q2 24 | 70.9% | 79.2% | ||
| Q1 24 | 66.7% | 78.9% |
营业利润率ABBVSTAA
| Q4 25 | 27.3% | — | ||
| Q3 25 | 12.1% | — | ||
| Q2 25 | 31.7% | — | ||
| Q1 25 | 28.0% | — | ||
| Q4 24 | -9.9% | -57.0% | ||
| Q3 24 | 26.5% | 6.4% | ||
| Q2 24 | 27.6% | 12.0% | ||
| Q1 24 | 22.7% | -2.9% |
净利率ABBVSTAA
| Q4 25 | 10.9% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | -0.1% | -69.9% | ||
| Q3 24 | 10.8% | 11.3% | ||
| Q2 24 | 9.5% | 7.5% | ||
| Q1 24 | 11.1% | -4.3% |
每股收益（稀释后）ABBVSTAA
| Q4 25 | $1.02 | — | ||
| Q3 25 | $0.10 | — | ||
| Q2 25 | $0.52 | — | ||
| Q1 25 | $0.72 | — | ||
| Q4 24 | $-0.03 | $-0.69 | ||
| Q3 24 | $0.88 | $0.20 | ||
| Q2 24 | $0.77 | $0.15 | ||
| Q1 24 | $0.77 | $-0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $230.5M |
| 总债务越低越好 | $58.9B | — |
| 股东权益账面价值 | $-3.3B | $397.3M |
| 总资产 | $134.0B | $509.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABBVSTAA
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.7B | — | ||
| Q2 25 | $6.5B | — | ||
| Q1 25 | $5.2B | — | ||
| Q4 24 | $5.6B | $230.5M | ||
| Q3 24 | $7.3B | $236.0M | ||
| Q2 24 | $13.2B | $235.2M | ||
| Q1 24 | $18.1B | $245.1M |
总债务ABBVSTAA
| Q4 25 | $58.9B | — | ||
| Q3 25 | $63.0B | — | ||
| Q2 25 | $63.0B | — | ||
| Q1 25 | $64.5B | — | ||
| Q4 24 | $60.3B | — | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
股东权益ABBVSTAA
| Q4 25 | $-3.3B | — | ||
| Q3 25 | $-2.6B | — | ||
| Q2 25 | $-183.0M | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $3.3B | $397.3M | ||
| Q3 24 | $6.0B | $428.1M | ||
| Q2 24 | $6.8B | $409.1M | ||
| Q1 24 | $8.0B | $392.8M |
总资产ABBVSTAA
| Q4 25 | $134.0B | — | ||
| Q3 25 | $133.9B | — | ||
| Q2 25 | $137.2B | — | ||
| Q1 25 | $136.2B | — | ||
| Q4 24 | $135.2B | $509.5M | ||
| Q3 24 | $143.4B | $537.6M | ||
| Q2 24 | $141.9B | $512.7M | ||
| Q1 24 | $148.9B | $492.5M |
负债/权益比ABBVSTAA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $642.0K |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $-5.1M |
| 自由现金流率自由现金流/营收 | 29.4% | -10.4% |
| 资本支出强度资本支出/营收 | 2.0% | 11.7% |
| 现金转化率经营现金流/净利润 | 2.87× | — |
| 过去12个月自由现金流最近4个季度 | $17.8B | $-7.7M |
8季度趋势，按日历期对齐
经营现金流ABBVSTAA
| Q4 25 | $5.2B | — | ||
| Q3 25 | $7.0B | — | ||
| Q2 25 | $5.2B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $7.0B | $642.0K | ||
| Q3 24 | $5.4B | $3.8M | ||
| Q2 24 | $2.3B | $-10.4M | ||
| Q1 24 | $4.0B | $21.7M |
自由现金流ABBVSTAA
| Q4 25 | $4.9B | — | ||
| Q3 25 | $6.6B | — | ||
| Q2 25 | $4.9B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $6.8B | $-5.1M | ||
| Q3 24 | $5.2B | $-2.4M | ||
| Q2 24 | $2.0B | $-16.6M | ||
| Q1 24 | $3.8B | $16.5M |
自由现金流率ABBVSTAA
| Q4 25 | 29.4% | — | ||
| Q3 25 | 42.1% | — | ||
| Q2 25 | 31.7% | — | ||
| Q1 25 | 10.5% | — | ||
| Q4 24 | 44.7% | -10.4% | ||
| Q3 24 | 35.9% | -2.7% | ||
| Q2 24 | 14.0% | -16.8% | ||
| Q1 24 | 31.3% | 21.3% |
资本支出强度ABBVSTAA
| Q4 25 | 2.0% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.9% | 11.7% | ||
| Q3 24 | 1.7% | 7.0% | ||
| Q2 24 | 1.7% | 6.3% | ||
| Q1 24 | 1.6% | 6.7% |
现金转化率ABBVSTAA
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | 0.38× | ||
| Q2 24 | 1.66× | -1.41× | ||
| Q1 24 | 2.95× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
